CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
- Conditions
- Fabry DiseasePregnancyPregnancy Complications
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 10
- Registration Number
- NCT06941025
- Locations
- 🇬🇧
No physical study sites - Decentralized, web-based registry, London, United Kingdom
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
- Conditions
- Epidermolysis BullosaJunctional Epidermolysis BullosaEpidermolysis Bullosa, DystrophicEpidermolysis Bullosa, JunctionalSkin AbnormalitiesCongenital AbnormalitiesConnective Tissue DiseaseCollagen DiseasesSkin DiseasesGenetic Diseases, Inborn
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 6
- Registration Number
- NCT06917690
- Locations
- 🇯🇵
Kurume University Hospital, Fukuoka, Japan
🇯🇵Niigata University Medical and Dental Hospital, Niigata, Japan
🇯🇵Hokkaido University Hospital, Sapporo-shi, Japan
A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 50
- Registration Number
- NCT06900816
- Locations
- 🇧🇬
Medical Centre Comac Medical Ltd., Sofia, Krasno Selo District, Bulgaria
Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 24
- Registration Number
- NCT06892756
- Locations
- 🇧🇬
Medical Centre Comac Medical Ltd, Sofia, Bulgaria
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers
- Conditions
- Pulmonary Fibrosis
- Interventions
- Drug: CHF10073 (Part 1 - SAD)Drug: Placebo (Part 1 - SAD)Drug: CHF10073 (Part 2 - MAD)Drug: Placebo (Part 2 - MAD)Drug: CHF10073 (Part 3)
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 132
- Registration Number
- NCT06746064
- Locations
- 🇧🇪
SGS Belgium NV Clinical Pharmacology Unit, Edegem, Belgium
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
- Conditions
- Fabry Disease
- Interventions
- Drug: Pegunigalsidase-alfa
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 100
- Registration Number
- NCT06663358
- Locations
- 🇺🇸
Infusion Associates, Grand Rapids, Michigan, United States
Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 359
- Registration Number
- NCT06480890
- Locations
- 🇨🇳
Site 156110 Beijing Jingmei Group Genetal Hospital, Beijing, Beijing, China
🇨🇳Site 156101 - The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Site 156113 - The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 24
- Registration Number
- NCT06395610
- Locations
- 🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
- Conditions
- Fabry Disease
- Interventions
- Drug: PRX-102 1 mg/kg every two weeks
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 22
- Registration Number
- NCT06328608
- Locations
- 🇺🇸
Phoenix Children's, Phoenix, Arizona, United States
🇺🇸Emory Genetics Clinical Trials Center, Atlanta, Georgia, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos)
- Conditions
- Asthma
- Interventions
- Drug: CHF5993 200/6/12.5 μg pMDI HFA-152aDrug: Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 836
- Registration Number
- NCT06264674
- Locations
- 🇦🇲
Yerevan State Medical University, Heratsi N 1 University Hospital Complex, Yerevan, Armenia
🇦🇲CITO Medical Center, Yerevan, Armenia
🇦🇲Armenia Republican Medical Center, Yerevan, Armenia